ENABLING TECHNOLOGIES FOR CELL-BASED CLINICAL TRANSLATION

Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy

Satsuki Yamada1,2 | D. Kent Arrell1 | Christian S. Rosenow1 | Jozef Bartunek3 | Atta Behfar1,4 | Andre Terzic1,5

1Department of Cardiovascular Medicine, Center for Regenerative Medicine, Marriott Heart Disease Research Program, Van Cleve Cardiac Regenerative Medicine Program, Rochester, Minnesota
2Geriatric Medicine, Rochester, Minnesota
3Cardiovascular Center, OLV Hospital, Aalst, Belgium
4Physiology & Biomedical Engineering, Rochester, Minnesota
5Molecular Pharmacology & Experimental Therapeutics, Clinical Genomics, Mayo Clinic, Rochester, Minnesota

Correspondence
Andre Terzic, MD, PhD, Molecular Pharmacology & Experimental Therapeutics, Clinical Genomics, Mayo Clinic, 200 First Street, SW, Rochester, MN 55905.
Email: terzic.andre@mayo.edu

Funding Information
Mayo Clinic Center for Regenerative Medicine; Michael S. and Mary Sue Shannon Family; Van Cleve Cardiac Regenerative Medicine Program; Marriott Family Foundation; Regenerative Medicine Minnesota, Grant/Award Number: 021218BT001; National Institutes of Health, Grant/Award Numbers: T32 HL07111, R01 HL134664

Abstract
Response to stem cell therapy in heart failure is heterogeneous, warranting a better understanding of outcome predictors. This study assessed left ventricular volume, a surrogate of disease severity, on cell therapy benefit. Small to large infarctions were induced in murine hearts to model moderate, advanced, and end-stage ischemic cardiomyopathy. At 1 month postinfarction, cardiomyopathic cohorts with comparable left ventricular enlargement and dysfunction were randomized 1:1 to those that either received sham treatment or epicardial delivery of cardiopoietic stem cells (CP). Progressive dilation and pump failure consistently developed in sham. In comparison, CP treatment produced significant benefit at 1 month post-therapy, albeit with an efficacy impacted by cardiomyopathic stage. Advanced ischemic cardiomyopathy was the most responsive to CP-mediated salvage, exhibiting both structural and functional restitution, with proteome deconvolution substantiating that cell therapy reversed infarction-induced remodeling of functional pathways. Moderate cardiomyopathy was less responsive to CP therapy, improving contractility but without reversing preexistent heart enlargement. In end-stage disease, CP therapy showed the least benefit. This proof-of-concept study thus demonstrates an optimal window, or “Goldilocks principle,” of left ventricular enlargement for maximized stem cell-based cardiac repair. Disease severity grading, prior to cell therapy, should be considered to inform regenerative medicine interventions.

KEYWORDS
cardiopoiesis, left ventricular volume, myocardial infarction, outcome, proteomics, regenerative medicine

INTRODUCTION

Stem cell therapy aims at restoring organ structure and function in the setting of ischemic heart failure, a leading cause of morbidity and mortality. The feasibility and safety of delivering stem cell biotherapies in infarcted hearts are established, yet a pressing challenge is the observed heterogeneity in outcomes. A practical approach to segregate potential responders from non-responders would contribute to standardized adoption.

Indeed, defining the guiding criteria for selection of best candidates prior to cell intervention is warranted. In heart failure, a recognized indicator of successful management is the reversal of left ventricular (LV) dilatation. Accordingly, this study assessed the predictive value of LV volume in the context of stem cell therapy for ischemic cardiomyopathy.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2019 The Authors. STEM CELLS TRANSLATIONAL MEDICINE published by Wiley Periodicals, Inc. on behalf of AlphaMed Press
2 | MATERIALS AND METHODS

2.1 | Model

Institutional Animal Care and Use Committee approved protocols were used. C57BL/6 or athymic nude mice (8 to 12 week old) underwent permanent ligation or 75-minutes occlusion followed by reperfusion of the left anterior descending coronary artery. One month postinfarction, surviving animals (n = 50) were randomized 1:1 into sham-treated (n = 25, 7 athymic nude, 18 C57BL/6) and cell-treated (n = 25 athymic nude) cohorts. Of note, cardiomyopathic phenotype postmyocardial infarction was equivalent in C57BL/6 vs athymic mice.

To limit cell-related variability, cardiopoietic stem (CP) cells served as a prototype of clinically tested regenerative biotherapy. Cardiopoietic stem (CP) cells served as a prototype of clinically tested regenerative biotherapy. Human CP cells were generated from bone marrow-derived mesenchymal stem cells following an established cardiopoiesis lineage-specifying protocol. CP cells (600 000 cells per heart in 15 μl media) were epicardially microinjected into 6 peri-infarcted sites of the LV anterior wall. The same procedure without cells (15 μl media injection into 6 sites) was applied to the sham cohort.

Significance statement
This article documents that cardiac chamber enlargement postinfarction is a predictor of cardiopoietic stem cell therapy response. Left ventricular size pretherapy could thus serve to guide the selection of ischemic heart failure candidates most suitable to receive a regenerative intervention.

FIGURE 1
Range of stem cell therapy benefit in myocardial infarction. A, In age-matched inbred mice devoid of heart failure risk factors, LV size demonstrated a narrow bell-shaped distribution, underscoring homogeneity before disease initiation. B, Left anterior descending artery was ligated from a distal to a proximal site, inducing mild to severe ischemic cardiomyopathy. ST elevation on the electrocardiogram and wall motion abnormality on ultrasound confirmed anterior wall myocardial infarction. Within 1 month postinfarction, LV end-diastolic volume increased from 43 ± 1 μl (n = 50; A) to 77 ± 4 μl (n = 50, p < .001). C, Along with structural alteration (B), LV pump function, measured by ejection fraction, decreased from 68% ± 1% preinfection to 37% ± 1% 1 month postinfarction (n = 50, p < .0001). Cardiomyopathic animals were randomized into those treated with epicardial delivery of CP cells (CP(+), n = 25) and sham (CP(−), n = 25). In contrast to progressive decline in sham, ejection fraction significantly recovered with CP therapy (1 month post-therapy, 30% ± 3% in CP(−), 45% ± 3% in CP(+), p < .0001). D, Similarly, pathological chamber dilatation was reversed in CP-treated cardiomyopathy (LV end-systolic volume post-therapy, 69 ± 10 μl in CP(−), 42 ± 5 μl in CP(+), p < .001). E, F, Comparing pretherapy and post-therapy unmasked individual variability in response. CP, cardiopoietic stem cells; LV, left ventricle.
2.2 | Endpoints

Therapeutic efficacy was assessed noninvasively by transthoracic echocardiography (Vevo3100 with MX400, Vevo2100 with MS400, FUJIFILM VisualSonics, Toronto, Canada) with prospective evaluation at preinfarction, 1 month postinfarction (pre-cell therapy), and 1 month post-cell therapy. LV ejection fraction (EF) was calculated as EF% = 100 × (LVEDV-LVESV)/LVEDV.16 EF improvement or worsening, within 1 month after cell therapy, was preset at >4% absolute increase and decrease, respectively, in line with clinical trial design.17 Reverse remodeling was defined by >15% reduction in LVESV.18 Echocardiographic data were independently analyzed in an investigator-blinded fashion by board-certified cardiologists/sonographers.

2.3 | Proteomics

At the end of the 2 month follow-up, LV protein extracts were analyzed by label-free quantitative tandem mass spectrometry, with resulting differentially expressed proteins (>twofold change, p < .05) interpreted by Ingenuity Pathway Analysis for response to functional or adverse cardiac effects19,20 induced by myocardial infarction with or without CP therapy.

2.4 | Statistics

The nonparametric Mann-Whitney U test or two-way repeated-measures ANOVA was used to evaluate significance between treatment arms (JMP Pro 14.1.0, SAS Institute Inc., Cary, North Carolina). Data are presented as mean ± SEM. A p-value <.05 was considered significant.

3 | RESULTS

Coronary ligation increased LVEDV from 43 ± 1 μl preinfarction to 77 ± 4 μl 1 month postinfarction (n = 50, p < .001; Figure 1A,B). Randomized into echocardiographically indistinguishable groups, cell-treated hearts compared to sham demonstrated rescue of cardiomyopathic traits. On average, EF postinfarction fell from 37% ± 2% to 30% ± 3% without cell treatment (CP(−); n = 25), yet recovered from 38% ± 1% to 45% ± 3% with cell therapy (CP(+); n = 25) reflecting cell-dependent functional recovery (p < .0001; Figure 1C). Structural compromise measured as abnormal increase in LVESV from 51 ± 5 to 69 ± 10 μl in sham contrasted (p < .001) with the restoration in CP(+) hearts from 48 ± 4 μl pretherapy to 42 ± 5 μl post-therapy (Figure 1D). Within age-matched cohorts, cell therapy...
benefited both male and female (p = .81) under permanent ligation or following ischemia/reperfusion injury (p = .25).

Notably, individual variability was observed within the stem cell treated group (Figure 1E,F). Pretherapy EF—the current standard for recipient selection—did not predict the degree of functional (p = .15) or structural (p = .26) responsiveness. Rather, pretherapy LVEDV—a widely use marker of disease-provoked pathologic remodeling—correlated with stem cell-induced benefit, namely EF recovery (Figure 2A) and reverse remodeling (Figure 2B). Specifically, EF improvement (>4% increase) was achieved in 70% (14/20) of the CP-treated infarcted cohort with a pretherapy LVEDV <100 μl. Reverse remodeling (>15% reduction in LVESV) was achieved in 77% (10/13) of CP(+) hearts within a pretherapy LVEDV window between 65 and 100 μl.

Accordingly, disease severity was categorized based on pretherapy LVEDV into moderate (LVEDV <65 μl, n = 14, 7 CP(−), 7 CP(+)), advanced (65 μl < LVEDV <100 μl, n = 26, 13 CP(−), 13 CP(+)), and end-stage (100 μl < LVEDV, n = 10, 5 CP(−), 5 CP(+); Figure 3). In moderate disease, CP therapy improved contractility (EF change, −6% ± 3% in CP(−), 8% ± 3% in CP(+), p < .01) but not existing LV dilation (LVESV change, 40% ± 19% in CP(−), 13% ± 8% in CP(+), p = .28; Figure 3A,B). Advanced ischemic cardiomyopathy was the most responsive to CP-mediated improvement, exhibiting both structural and functional restitution (EF change, −3% ± 2% in CP(−), 10% ± 2% in CP(+), p < .001; LVESV change, 15% ± 11% in CP(−), −27% ± 6% in CP(+), p < .01; Figure 3C,D). In end-stage cardiomyopathy, CP therapy induced least benefit (EF change, −18% ± 4% in CP(−), −3% ± 4% in CP(+), p < .05; LVESV change, 59% ± 12% in CP(−), −9% ± 6% in CP(+), p < .01; Figure 3E,F).

Improved EF combined with reverse remodeling are recommended goals in heart failure management, and were here achieved in >60% of advanced (62%, 8/13), compared to ≤20% of moderate or end-stage disease (Figure 4A). The molecular response within the advanced stage cohort was independently evaluated at proteomic level, where 79 proteins were found to distinguish CP-treated from CP-untreated infarcted hearts (Figure 4B). Functional

**FIGURE 3** Grading of cardiac dilatation identifies a window of optimal response to stem cell therapy. At time of randomization (pretherapy), echocardiographic parameters were equivalent between ischemic cardiomyopathy cohorts. Prospective 1 month follow-up (post-therapy), validated the superiority of the CP-treated (CP(+)) over CP-untreated (CP(−)) cohort across all stages of cardiomyopathy, yet the effectiveness depended on the pretherapy LV volume. Specifically, in moderate cardiomyopathy (pretherapy LVEDV <65 μl; A, B), CP therapy improved EF (−6% ± 3% in CP(−), 8% ± 3% in CP(+), p < .01; A bottom), but did not change the natural course of progressive LV dilatation (A top). Advanced ischemic cardiomyopathy (65 μl < pretherapy LVEDV <100 μl; C, D) was most responsive to CP-mediated improvement with both structural (C top) and functional (C bottom) restitution. In end-stage cardiomyopathy (100 μl < pretherapy LVEDV; E, F), cell therapy-hampered disease progression into terminal heart failure which was unavoidable in the untreated cohort. However, CP intervention fell short in salvaging the underlying end-stage conditions (F). CP, cardiopoietic stem cells; EF, ejection fraction; LV, left ventricle; LVEDV, LV end-diastolic volume

**Disease severity pre-therapy**

![Graphs showing disease severity pre-therapy](image-url)
enrichment analysis revealed that the CP therapy-dependent proteome validated therapeutic responsiveness, with infarction-provoked cardiac dilation \( (p < .01) \) and contractile failure \( (p < .01) \) both predicted to be mitigated on the basis of proteome remodeling, thus pinpointing the molecular reach of disease rescue.

4 | DISCUSSION

The present study demonstrates a window for best stem cell therapy outcomes determined within a median range of LV dilatation post-infarction. This “Goldilocks principle” was documented by leveraging standardized cell production and delivery protocols, in the setting of comorbidity-free anterior myocardial infarction. In contrast, pretherapy EF, which has been traditionally used to recruit patients for cell therapy, did not predict recipient response.

The degree of LV dilatation has been linked to a range of efficacy experienced with pharmacological, device or surgical treatments.\(^{23,24}\) It is further unmasked herein as a determinant of stem cell-promoted cardiac repair. in vivo functional and structural restoration was reinforced by molecular validation at proteome level. The significance of LV size in prioritizing best responders is potentially applicable in practice as supported by recent clinical subanalysis in both ischemic and non-ischemic cardiomyopathy using multiple cell types.\(^{17,21,22,25}\) Further prospective investigation across the translational axis is now required to certify the utility of LV volumes in screening candidates for optimized regenerative biotherapy in heart failure.

5 | CONCLUSION

Cell therapy benefit depends on infarction-induced cardiac dilatation and could inform recipient stratification to maximize regenerative outcome.

ACKNOWLEDGMENTS

The authors thank Katrina M. Tollefsrud, Kristin W. O’Meara, and Diane M. Jech for echocardiography analysis; Jonathan J. Nesbitt and Ryounghoon Jeon for microsurgery; Ruben J. Crespo-Diaz and Soulmaz Boroumand for stem cell culture. This work was supported
VENTRICULAR REMODELING IN ISCHEMIC HEART FAILURE STRATIFIES RESPONDERS TO STEM CELL THERAPY

Satsuki Yamada

CONFLICT OF INTEREST

S.Y., A.B., and A.T. are coinventors on regenerative sciences related intellectual property disclosed to Mayo Clinic. Previously, Mayo Clinic has administered research grants from Celyad. Mayo Clinic, A.B., and A.T. have interests in Rion LLC.

AUTHOR CONTRIBUTIONS

S.Y.: conception and design, financial support, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; D.K.A.: conception and design, collection and assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; C.S.R.: collection and assembly of data, data analysis and interpretation, final approval of manuscript; J.B.: provision of study material, data interpretation, final approval of manuscript; A.T.: conception and design, financial support, administrative support, provision of study material, data interpretation, final approval of manuscript; A.B.: conception and design, financial support, administrative support, provision of study material, data analysis and interpretation, manuscript writing, final approval of manuscript.

ORCID

Satsuki Yamada https://orcid.org/0000-0003-3072-4539

REFERENCES

1. Fernández-Avilés F, Sanz-Ruiz R, Climent AM, et al. Global position paper on cardiovascular regenerative medicine. Eur Heart J. 2017;38:2532-2546.
2. Banerjee MN, Bolli R, Hare JM. Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions. Circ Res. 2018;123:266-287.
3. Normand C, Kaye DM, Povsic TJ, et al. Beyond pharmacological treatment: an insight into therapies that target specific aspects of heart failure pathophysiology. Lancet. 2019;393:1045-1055.
4. Braunwald E. Cell-based therapy in cardiac regeneration: an overview. Circ Res. 2018;123:132-137.
5. Landin AM, Hare JM. The quest for a successful cell-based therapeutic approach for heart failure. Eur Heart J. 2017;38:661-664.
6. Blau HM, Daley GQ. Stem cells in the treatment of disease. N Engl J Med. 2019;380:1748-1760.
7. Chien KR, Frisen J, Fritsche-Danielson R, Melton DA, Murry CE, Weissman IL. Regenerating the field of cardiovascular cell therapy. Nat Biotechnol. 2019;37:232-237.
8. Mensáché P. Cell therapy trials for heart regeneration—lessons learned and future directions. Nat Rev Cardiol. 2018;15:659-671.
9. Konstam MA, Kramer DG, Patel AR, Maron MS, Udelson JE. Left ventricular remodeling in heart failure: current concepts in clinical significance and assessment. JACC Cardiovasc Imaging. 2011;4:98-108.
10. Heusch G, Libby P, Gersh B, et al. Cardiovascular remodelling in coronary artery disease and heart failure. Lancet. 2014;383:1933-1943.
11. Kim GH, Uriel N, Burkhoff D. Reverse remodelling and myocardial recovery in heart failure. Nat Rev Cardiol. 2018;15:83-96.
12. Terzic A, Behfar A. Stem cell therapy for heart failure: ensuring regenerative proficiency. Trends Cardiovasc Med. 2016;26:395-404.
13. Behfar A, Yamada S, Crespo-Díaz R, et al. Guided cardiopoiesis enhances therapeutic benefit of bone marrow human mesenchymal stem cells in chronic myocardial infarction. J Am Coll Cardiol. 2010;56:721-734.
14. Bartunek J, Behfar A, Dolatabadi D, et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol. 2013;61:2329-2338.
15. Yamada S, Nelson TJ, Kane GC, et al. Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. J Physiol. 2013;591:4335-4349.
16. Yamada S, Arrell DK, Kane GC, et al. Mechanical dyssynchrony precedes QRS widening in ATP-sensitive K⁺ channel-deficient dilated cardiomyopathy. J Am Heart Assoc. 2013;2:e000410.
17. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J. 2017;38:648-660.
18. Waring AA, Litwin SE. Redefining reverse remodeling: can echocardiography refine our ability to assess response to heart failure treatments? J Am Coll Cardiol. 2016;68:1277-1280.
19. Zlatkovic-Lindor J, Arrell DK, Yamada S, Nelson TJ, Terzic A. ATP-sensitive K⁺ channel-deficient dilated cardiomyopathy proteome remodeled by embryonic stem cell therapy. Stem Cells. 2010;28:1355-1367.
20. Yamada S, Arrell DK, Martinez-Fernandez A, et al. Regenerative therapy prevents heart failure progression in dysynchronous nonischemic narrow QRS cardiomyopathy. J Am Heart Assoc. 2015;4:e001614.
21. Teerlink JR, Metra M, Filippatos GS, et al. Benefit of cardiopoietic mesenchymal stem cell therapy on left ventricular remodeling: results from the congestive heart failure cardiopoietic regenerative therapy (CHART-1) study. J Am Coll Cardiol. 2017;69:1520-1529.
22. Frijak S, Jaklic M, Poglajen G, et al. End-diastolic volume predicts response to cell therapy in patients with nonischemic dilated cardiomyopathy. Circulation. 2018;138:A12846.
23. Varma N, Sogaard P, Bax JJ, et al. Interaction of left ventricular size and sex on outcome of cardiac resynchronization therapy among patients with a narrow QRS duration in the EchoCRT trial. J Am Heart Assoc. 2018;7:e009592.
24. Yingchoncharoen T, Negishi T, Stanton T, Marwick TH. Incremental value of three-dimensional echocardiography in the evaluation of left ventricular size in mitral regurgitation: a follow-up study after mitral valve surgery. J Am Soc Echocardiogr. 2014;27:608-615.
25. Bartunek J, Terzic A, Behfar A, Wijns W. Clinical experience with cardiopoietic stem cell interventions. Circ Res. 2018;122:1344-1346.

How to cite this article: Yamada S, Arrell DK, Rosenow CS, Bartunek J, Behfar A, Terzic A. Ventricular remodeling in ischemic heart failure stratifies responders to stem cell therapy. STEM CELLS Transl Med. 2020;9:74–79. https://doi.org/10.1002/sctm.19-0149